On January 3, 2018 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, reported that Matthew R. Patterson, President and Chief Executive Officer, will provide a corporate overview and 2018 outlook at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA (Press release, Audentes Therapeutics, JAN 3, 2018, View Source;p=RssLanding&cat=news&id=2324604 [SID1234522861]). The presentation is scheduled for Wednesday, January 10, 2018, at 2:30 pm PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentations, please visit the Events & Presentations page within the Investors & News section of the Audentes website. Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conferences.

On January 3, 2018 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported that management will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:30 p.m. ET (9:30 a.m. PT) (Press release, Vertex Pharmaceuticals, JAN 3, 2018, View Source [SID1234522859]). The audio portion of management’s remarks can be accessed live through Vertex’s website, www.vrtx.com in the "Investors" section under the "News and Events" page.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the company announced today that it will report its fourth-quarter and full-year 2017 financial results on Wednesday, January 31 after the markets close. In conjunction with the announcement, management will host a conference call that day at 4:30 p.m. ET. To participate in the conference call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The call will also be available as a live and archived webcast on Vertex’s website.

On January 4, 2018 IntelGenx Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") reported that its President and Chief Executive Officer, Dr. Horst Zerbe, is scheduled to present an overview of the Company’s business at the 10 th Annual Biotech Showcase conference on Tuesday, January 9 at 9:00 a.m. Pacific Time at the Hilton San Francisco Union Square Hotel (Press release, IntelGenx, JAN 3, 2018, View Source [SID1234522909]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and archived for 90 days on the Company’s website, at www.intelgenx.com , under "Investors".

Andre Godin , Executive Vice President and Chief Financial Officer, and Dr. Dana Matzen , Vice President Business and Corporate Development, from IntelGenx will also be available for one-on-one meetings in San Francisco from January 8 through 10 . To arrange an investor meeting with IntelGenx , please contact Stephen Kilmer ( [email protected] ) and to arrange a business development meeting please contact Dr. Laëtitia Rodes ( [email protected] ) .

On January 3, 2018 Angiochem Inc. and Xinogen (Hong Kong) Pharma Co. Ltd. ("Xinogen"), a wholly-owned subsidiary of Beijing Shenogen Pharma Group Ltd. entered a license and collaboration agreement to develop and commercialize ANG1005 in China for treatment of patients with leptomeningeal carcinomatosis from breast cancer. (Press release, AngioChem, JAN 3, 2018, View Source [SID1234573598]). Xinogen was granted exclusive rights to develop and commercialize ANG1005 in the Greater China region. In return, Angiochem will receive upfront and milestone payments as well as a royalty based on future product sales.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Angiochem is currently developing ANG1005 for treatment of leptomeningeal carcinomatosis from breast cancer. The company’s next clinical trial is due to start in 2018.

"Angiochem is looking forward to collaborating with Xinogen," said John Huss, Executive Chairman of Angiochem. Dr. Kun Meng, CEO of Beijing Shenogen Pharma Group Ltd, also expressed his enthusiasm and confidence about collaborating with Angiochem.

On January 3, 2018 LabCorp (NYSE: LH) reported that it will participate at the 36th Annual J.P. Morgan Healthcare Conference (Press release, LabCorp, JAN 3, 2018, View Source;p=RssLanding&cat=news&id=2324630 [SID1234522842]). LabCorp’s presentation is scheduled for Tuesday, January 9, 2018 at 9:30 am (PT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay.